Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • familial chylomicronaemia syndrome

    - PMLiVE

    Arrowhead’s RNAi therapeutic plozasiran shows promise in familial chylomicronaemia syndrome

    There are currently no therapies in the US specifically approved to treat the rare genetic disorder

    - PMLiVE

    Ionis shares positive late-stage results for olezarsen in familial chylomicronaemia syndrome

    The rare genetic disease is estimated to affect up to 13 people per million in the US

    - PMLiVE

    GSK to acquire exclusive rights to Janssen’s hepatitis B therapy in $1bn deal

    GSK will evaluate the therapy in combination with its own hepatitis B treatment

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links